Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462574 · ClinicalTrials.gov registry record
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
A clinical trial of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT05462574 is a study of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 75 participants, below the 690-participant average among 3 other Idiopathic Pulmonary Arterial Hypertension trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05462574, a study of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2027-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05462574
The ClinicalTrials.gov registry entry for NCT05462574 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 690-participant average among 3 other Idiopathic Pulmonary Arterial Hypertension trials with a reported enrollment target (89% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Idiopathic Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT05462574 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05462574 about?
NCT05462574 is a clinical study titled "Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)". The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.
What is the current status of trial NCT05462574?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2023-01-17. Estimated completion is 2027-09-30.
What conditions does trial NCT05462574 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.
What interventions are being tested in trial NCT05462574?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05462574?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05462574 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hormonal, Metabolic, and Signaling Interactions in PAH
RECRUITING
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
RECRUITING
Explore more on PlainTrial
Idiopathic Pulmonary Arterial Hypertension
All registered trials for this condition
Heritable Pulmonary Arterial Hypertension
All registered trials for this condition
Tennessee
All trials with a study site in Tennessee
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.